Reports for APOTEX INC
Company Name
APOTEX INC
Totals |
||
Shortage reports |
3356 |
|
| Actual shortage: | 218 (6%) | |
| Anticipated shortage: | 0 (0%) | |
| Avoided shortage: | 10 (0%) | |
| Resolved: | 3128 (93%) | |
Discontinuation Reports |
359 |
|
| To be discontinued: | 24 (7%) | |
| Discontinued: | 335 (93%) | |
| Reversed: | 0 (0%) | |
Late reports |
144 (4%) |
|
Overdue reports |
61 (25%) |
|
Shortage reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-CANDESARTAN | 32MG | TABLET | Resolved | 2020-05-13 | 2020-09-21 | 114928 |
| APO-CANDESARTAN | 16MG | TABLET | Resolved | 2020-06-24 | 2021-06-14 | 118761 |
| APO-CANDESARTAN | 16MG | TABLET | Resolved | 2020-06-24 | 2020-09-21 | 118763 |
| APO-CANDESARTAN | 4MG | TABLET | Resolved | 2020-10-21 | 2021-03-15 | 126768 |
| APO-CANDESARTAN | 32MG | TABLET | Actual shortage | 2022-03-11 | 2022-03-11 | 156534 |
| APO-CANDESARTAN | 4MG | TABLET | Actual shortage | 2022-08-12 | 2022-08-12 | 166589 |
| APO-CANDESARTAN | 8MG | TABLET | Actual shortage | 2022-08-12 | 2022-08-12 | 166592 |
| APO-CANDESARTAN | 16MG | TABLET | Actual shortage | 2022-08-12 | 2022-08-12 | 166595 |
| APO-CANDESARTAN | 16MG | TABLET | Resolved | 2021-05-14 | 2021-07-30 | 139406 |
| APO-CANDESARTAN | 32MG | TABLET | Actual shortage | 2021-10-22 | 2021-10-22 | 147815 |
| APO-CANDESARTAN | 16MG | TABLET | Resolved | 2017-03-11 | 2017-06-27 | 639 |
| APO-CANDESARTAN | 4MG | TABLET | Resolved | 2017-03-12 | 2018-09-09 | 706 |
| APO-CANDESARTAN | 32MG | TABLET | Resolved | 2017-03-20 | 2020-02-25 | 3516 |
| APO-CANDESARTAN TABLETS | 16MG | TABLET | Resolved | 2025-03-20 | 2025-04-11 | 253078 |
| APO-CANDESARTAN TABLETS | 8MG | TABLET | Resolved | 2025-01-30 | 2025-03-14 | 249077 |
| APO-CANDESARTAN TABLETS | 16MG | TABLET | Resolved | 2024-09-20 | 2025-03-07 | 238233 |
| APO-CANDESARTAN TABLETS | 4MG | TABLET | Resolved | 2024-10-04 | 2025-01-17 | 239355 |
| APO-CANDESARTAN TABLETS | 4MG | TABLET | Resolved | 2024-10-04 | 2024-12-06 | 239358 |
| APO-CANDESARTAN TABLETS | 16MG | TABLET | Resolved | 2024-12-12 | 2025-03-07 | 245502 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Resolved | 2017-09-07 | 2018-02-26 | 21199 |
Discontinuation reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-TIMOP | 0.5% | SOLUTION | Discontinued | 2019-01-03 | 2019-01-03 | 70894 |
| APO-TIMOP GEL | Discontinued | 2019-01-03 | 2019-01-03 | 71020 | ||
| APO-TIMOP | Discontinued | 2019-01-02 | 2019-01-02 | 70818 | ||
| APO-TOLTERODINE | 1MG | TABLET | Discontinued | 2018-09-08 | 2019-01-17 | 60822 |
| APO-TOLTERODINE | 2MG | TABLET | Discontinued | 2018-09-08 | 2018-11-09 | 60825 |
| APO-TOLTERODINE | 2MG | TABLET | Discontinued | 2018-09-08 | 2019-06-12 | 60828 |
| APO-TRAZODONE TABLETS 100MG | 100MG | TABLET | Discontinued | 2018-09-08 | 2018-09-15 | 60831 |
| APO-TRAZODONE TABLETS 50MG | 50MG | TABLET | Discontinued | 2018-09-08 | 2018-09-15 | 60834 |
| APO-VALACYCLOVIR | 500MG | TABLET | Discontinued | 2018-09-08 | 2018-09-15 | 60840 |
| APO-VALGANCICLOVIR | 450MG | TABLET | Discontinued | 2018-09-08 | 2018-09-15 | 60843 |
| APO-VALPROIC ACID ORAL SOLUTION | 250MG | SOLUTION | Discontinued | 2023-09-26 | 2023-11-02 | 205310 |
| APO-VALSARTAN | Discontinued | 2019-01-03 | 2019-01-03 | 71029 | ||
| APO-VALSARTAN | Discontinued | 2019-01-03 | 2019-01-03 | 71032 | ||
| APO-VALSARTAN | Discontinued | 2019-01-03 | 2019-01-03 | 71035 | ||
| APO-VALSARTAN | Discontinued | 2019-01-03 | 2019-01-03 | 71038 | ||
| APO-VALSARTAN/HCTZ | Discontinued | 2019-01-03 | 2019-01-03 | 71044 | ||
| APO-VALSARTAN/HCTZ | Discontinued | 2019-01-03 | 2019-01-03 | 71048 | ||
| APO-VALSARTAN/HCTZ | Discontinued | 2019-01-03 | 2019-01-03 | 71051 | ||
| APO-VALSARTAN/HCTZ | 12.5MG 160MG | TABLET | Discontinued | 2019-01-03 | 2019-01-03 | 71054 |
| APO-VALSARTAN/HCTZ | Discontinued | 2019-01-03 | 2019-01-03 | 71057 |